HC Wainwright Reiterates $8.00 Price Target for Immune Design (IMDZ)
IMDZ has been the topic of several other research reports. Zacks Investment Research raised shares of Immune Design from a sell rating to a hold rating in a research note on Wednesday, October 3rd. Royal Bank of Canada reaffirmed an outperform rating and issued a $11.00 price target on shares of Immune Design in a research note on Friday, October 12th. Finally, Leerink Swann downgraded shares of Immune Design from an outperform rating to a market perform rating in a research note on Friday, October 12th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Immune Design currently has a consensus rating of Buy and an average target price of $7.25.
IMDZ stock traded down $0.03 during trading on Wednesday, hitting $1.48. The company had a trading volume of 238,195 shares, compared to its average volume of 1,018,651. The company has a market capitalization of $73.21 million, a PE ratio of -0.85 and a beta of 2.54. Immune Design has a 52-week low of $1.29 and a 52-week high of $5.05.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Tiverton Asset Management LLC purchased a new position in Immune Design during the 2nd quarter valued at about $176,000. Essex Investment Management Co. LLC purchased a new position in Immune Design during the 2nd quarter valued at about $192,000. Bank of America Corp DE increased its position in Immune Design by 231.9% during the 2nd quarter. Bank of America Corp DE now owns 46,754 shares of the biotechnology company’s stock valued at $212,000 after purchasing an additional 32,669 shares during the period. DRW Securities LLC increased its position in Immune Design by 59.2% during the 2nd quarter. DRW Securities LLC now owns 58,900 shares of the biotechnology company’s stock valued at $268,000 after purchasing an additional 21,900 shares during the period. Finally, Alps Advisors Inc. purchased a new position in Immune Design during the 2nd quarter valued at about $318,000. 49.36% of the stock is currently owned by institutional investors and hedge funds.
About Immune Design
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.
See Also: Exchange-Traded Funds (ETFs)
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.